Request Deal Involvement
BridgeBio Oncology Therapeutics to go public via a merger with Helix Acquisition Corp II in a $949m deal.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Goodwin Procter
financial advisors
Piper Sandler
financial advisors
Leerink Partners
financial advisors
Cantor Capital Partners
legal advisors
White & Case
financial advisors
Lincoln International
legal advisors to financial advisors
Covington & Burling
financial advisors
Morgan Stanley
financial advisors
Oppenheimer & Co
financial advisors
Leerink Partners
legal advisors
Kirkland & Ellis
or
Principals
bidder
OCTAGON CAPITAL
bidder
SURVEYOR CAPITAL
bidder
NOVO HOLDINGS A/S
target
BRIDGEBIO ONCOLOGY THERAPEUTICS
bidder
DEERFIELD MANAGEMENT COMPANY
bidder
ENAVATE SCIENCES
bidder
HELIX ACQUISITION CORP II
bidder
CORMORANT ASSET MANAGEMENT
bidder
ADAR1 CAPITAL MANAGEMENT
bidder
EVENTIDE ASSET MANAGEMENT
bidder
WELLINGTON MANAGEMENT
bidder
OMEGA FUNDS
bidder
PARADIGM BIOCAPITAL
bidder
STEMPOINT CAPITAL
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite